NYSE:AGN - Allergan Stock Price, Price Target & More

$157.12 +0.22 (+0.14 %)
(As of 04/26/2018 01:42 AM ET)
Previous Close$156.90
Today's Range$154.90 - $157.22
52-Week Range$142.81 - $256.80
Volume1.70 million shs
Average Volume3.20 million shs
Market Capitalization$55.70 billion
P/E Ratio9.61
Dividend Yield1.80%
Beta1.18

About Allergan (NYSE:AGN)

Allergan logoAllergan plc, a specialty pharmaceutical company, develops, manufactures, markets, and distributes medical aesthetics, biosimilar, and over-the-counter pharmaceutical products worldwide. It operates through US Specialized Therapeutics, US General Medicine, and International segments. The company offers a portfolio of products that provide treatment for the central nervous system, gastroenterology, women's health and urology, ophthalmology, neurosciences, medical aesthetics, dermatology, plastic surgery, liver disease, inflammation, metabolic syndromes, and fibrosis, as well as Alzheimer's disease. It is also involved in developing ocular implants that reduce intraocular pressure associated with glaucoma; medical devices for the correction of prominent ears; and intranasal neurostimulation devices, as well as other dry eye products. In addition, the company distributes generic and branded pharmaceutical products primarily to independent and chain pharmacies, nursing homes, mail order pharmacies, hospitals, clinics, and physician offices. Further, it develops a portfolio of breast implants and tissue expanders; and RM-131 (relamorelin), a peptide ghrelin agonist for the treatment of diabetic gastroparesis. The company has licensing agreement with Assembly Biosciences, Inc.; Mimetogen Pharmaceuticals, Inc.; Almirall, S.A; Naurex, Inc.; and Merck & Co. The company was formerly known as Actavis plc and changed its name to Allergan plc in June 2015. Allergan plc was founded in 1983 and is headquartered in Dublin, Ireland.

Receive AGN News and Ratings via Email

Sign-up to receive the latest news and ratings for AGN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
SymbolNYSE:AGN
CUSIP01849010
Phone353-1435-7700

Debt

Debt-to-Equity Ratio0.38%
Current Ratio1.16%
Quick Ratio1.06%

Price-To-Earnings

Trailing P/E Ratio9.61
Forward P/E Ratio10.08
P/E Growth1.14

Sales & Book Value

Annual Sales$15.94 billion
Price / Sales3.43
Cash Flow$39.3784 per share
Price / Cash3.99
Book Value$207.19 per share
Price / Book0.76

Profitability

EPS (Most Recent Fiscal Year)$16.35
Net Income$-4,125,500,000.00
Net Margins-26.32%
Return on Equity8.43%
Return on Assets4.75%

Miscellaneous

Employees17,800
Outstanding Shares348,340,000

How to Become a New Pot Stock Millionaire

Allergan (NYSE:AGN) Frequently Asked Questions

What is Allergan's stock symbol?

Allergan trades on the New York Stock Exchange (NYSE) under the ticker symbol "AGN."

How often does Allergan pay dividends? What is the dividend yield for Allergan?

Allergan announced a quarterly dividend on Friday, February 9th. Shareholders of record on Wednesday, February 28th will be given a dividend of $0.72 per share on Wednesday, March 28th. This represents a $2.88 dividend on an annualized basis and a yield of 1.83%. The ex-dividend date of this dividend is Tuesday, February 27th. This is an increase from Allergan's previous quarterly dividend of $0.70. View Allergan's Dividend History.

How will Allergan's stock buyback program work?

Allergan announced that its Board of Directors has approved a share buyback program on Tuesday, September 26th 2017, which allows the company to repurchase $2,000,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization allows the company to buy up to 2.8% of its shares through open market purchases. Shares repurchase programs are typically an indication that the company's board of directors believes its stock is undervalued.

How were Allergan's earnings last quarter?

Allergan (NYSE:AGN) posted its earnings results on Tuesday, February, 6th. The company reported $4.86 earnings per share for the quarter, beating the consensus estimate of $4.74 by $0.12. The firm earned $4.33 billion during the quarter, compared to analysts' expectations of $4.28 billion. Allergan had a negative net margin of 26.32% and a positive return on equity of 8.43%. The firm's revenue for the quarter was up 12.0% compared to the same quarter last year. During the same quarter in the prior year, the company posted $3.90 earnings per share. View Allergan's Earnings History.

When is Allergan's next earnings date?

Allergan is scheduled to release their next quarterly earnings announcement on Monday, April, 30th 2018. View Earnings Estimates for Allergan.

What guidance has Allergan issued on next quarter's earnings?

Allergan updated its FY18 earnings guidance on Tuesday, February, 6th. The company provided earnings per share (EPS) guidance of $15.25-16.00 for the period, compared to the Thomson Reuters consensus EPS estimate of $15.42. The company issued revenue guidance of $15.0-15.3 billion, compared to the consensus revenue estimate of $15.25 billion.Allergan also updated its Q1 guidance to $3.20-3.40 EPS.

What price target have analysts set for AGN?

22 brokers have issued 1 year target prices for Allergan's shares. Their forecasts range from $160.07 to $265.00. On average, they expect Allergan's stock price to reach $220.1535 in the next twelve months. View Analyst Ratings for Allergan.

What are Wall Street analysts saying about Allergan stock?

Here are some recent quotes from research analysts about Allergan stock:
  • 1. Cantor Fitzgerald analysts commented, "Key takeaways from the quarter: 1) AGN has more important pipeline catalysts in 2018 including those for the CGRPs for migraine, abicipar for AMD, and the FDA approval of Esmya. 2) LOEs and mix will impact AGN’s margins in the near term, but its cost-cutting initiatives will buffer the impact with longer- term margin expansion driven by pipeline success. 3) ~One-third of AGN’s sales comes from cash pay products and Botox Therapeutics, and AGN believes this will grow to ~45% of sales by 2022. 4) Capital allocation strategy is sound with AGN on its way to achieving a 3x leverage ratio, and maintaining its investment grade rating, AGN will be opportunistic on its $2B share buyback and is committed to growing its dividend. 5) As of 12/31/17, AGN had cash & equivalents of $6.5B and debt of $30.1B, CFLO from operations increased to ~$2.1B in 4Q17. 6) Top line results from ACHIEVE I (UBR-MD-01) study demonstrated efficacy, safety and tolerability, study met co-primary endpoints in the first of two Phase 3 studies, there were 6 cases with aminotransferase (ALT or AST) elevations greater than 3x the upper limit of normal, and there were alternative explanations in all cases." (2/6/2018)
  • 2. According to Zacks Investment Research, "Allergan’s products like Botox and Linzess and new products such as Viberzi, Namzaric and Vraylar support sales. It also boasts a strong branded pipeline. Biosimilars also represent significant opportunity. However, while we remain optimistic about the company’s growth prospects, it is facing potential loss of exclusivity for many products in 2018 including Namenda XR and Restasis. In October 2017, a Texas federal district court invalidated four of the six patents covering Restasis, potentially opening doors for early generic competition. Though Restasis patents are scheduled to expire in August 2024, a generic version may be launched as early as mid-2018. Also, new competition for key growth drivers, Restasis and Linzess, is an investor concern. Allergan’s shares underperformed the industry in the past six months. " (1/2/2018)

Are investors shorting Allergan?

Allergan saw a drop in short interest in March. As of March 15th, there was short interest totalling 6,391,424 shares, a drop of 39.1% from the February 28th total of 10,501,103 shares. Based on an average daily trading volume, of 4,617,063 shares, the short-interest ratio is currently 1.4 days. Approximately 1.9% of the company's stock are short sold.

Who are some of Allergan's key competitors?

Who are Allergan's key executives?

Allergan's management team includes the folowing people:
  • Mr. Brenton L. Saunders, Chairman, Chief Exec. Officer and Pres (Age 48)
  • Mr. William Meury, Exec. VP & Chief Commercial Officer (Age 50)
  • Mr. Matthew M. Walsh, Exec. VP & CFO (Age 51)
  • Mr. Wayne R. Swanton, Exec. VP of Global Operations (Age 50)
  • Mr. James C. D'Arecca, Chief Accounting Officer (Age 47)

Has Allergan been receiving favorable news coverage?

Media headlines about AGN stock have trended somewhat positive recently, Accern Sentiment reports. The research group identifies positive and negative news coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Allergan earned a media sentiment score of 0.09 on Accern's scale. They also gave news articles about the company an impact score of 44.63 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company's share price in the next several days.

How do I buy shares of Allergan?

Shares of AGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Allergan's stock price today?

One share of AGN stock can currently be purchased for approximately $157.12.

How big of a company is Allergan?

Allergan has a market capitalization of $55.70 billion and generates $15.94 billion in revenue each year. The company earns $-4,125,500,000.00 in net income (profit) each year or $16.35 on an earnings per share basis. Allergan employs 17,800 workers across the globe.

How can I contact Allergan?

Allergan's mailing address is CLONSHAUGH BUSINESS AND TECHNOLOGY PARK COOLOCK, DUBLIN L2, D17 E400. The company can be reached via phone at 353-1435-7700 or via email at [email protected]


MarketBeat Community Rating for Allergan (AGN)

Community Ranking:  3.4 out of 5 (star star star)
Outperform Votes:  1,006 (Vote Outperform)
Underperform Votes:  458 (Vote Underperform)
Total Votes:  1,464
MarketBeat's community ratings are surveys of what our community members think about Allergan and other stocks. Vote "Outperform" if you believe AGN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AGN will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Allergan (NYSE:AGN) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
22 Wall Street analysts have issued ratings and price targets for Allergan in the last 12 months. Their average twelve-month price target is $220.1535, suggesting that the stock has a possible upside of 40.12%. The high price target for AGN is $265.00 and the low price target for AGN is $160.07. There are currently 7 hold ratings and 15 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.682.702.612.60
Ratings Breakdown: 0 Sell Rating(s)
7 Hold Rating(s)
15 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
6 Hold Rating(s)
14 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
7 Hold Rating(s)
11 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
8 Hold Rating(s)
12 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $220.1535$223.7405$227.1294$251.9444
Price Target Upside: 40.12% upside39.56% upside20.77% upside33.81% upside

Allergan (NYSE:AGN) Consensus Price Target History

Price Target History for Allergan (NYSE:AGN)

Allergan (NYSE:AGN) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/24/2018CitigroupReiterated RatingBuy -> Buy$220.00 -> $200.00MediumView Rating Details
4/23/2018Evercore ISIInitiated CoverageOutperformLowView Rating Details
4/22/2018Credit Suisse GroupSet Price TargetBuy$215.00LowView Rating Details
4/17/2018Stifel NicolausInitiated CoverageHold -> Hold$192.00LowView Rating Details
4/16/2018CowenSet Price TargetBuy$255.00LowView Rating Details
4/12/2018Cantor FitzgeraldSet Price TargetHold$191.00LowView Rating Details
4/12/2018Deutsche BankReiterated RatingBuyLowView Rating Details
3/26/2018Leerink SwannReiterated RatingOutperformHighView Rating Details
3/15/2018JPMorgan ChaseSet Price TargetBuy$265.00LowView Rating Details
3/14/2018Royal Bank of CanadaReiterated RatingBuy$213.00LowView Rating Details
3/1/2018Morgan StanleyLower Price TargetOverweight -> Overweight$200.00 -> $181.00HighView Rating Details
2/23/2018SunTrust BanksInitiated CoverageBuy -> Buy$200.00LowView Rating Details
2/7/2018Bank of AmericaBoost Price TargetBuy -> Buy$208.00 -> $215.00LowView Rating Details
1/29/2018BarclaysUpgradeEqual Weight -> Overweight$220.00 -> $230.00LowView Rating Details
1/10/2018UBSSet Price TargetBuy$250.00MediumView Rating Details
1/5/2018Wells FargoSet Price TargetBuy$245.00LowView Rating Details
12/7/2017ArgusDowngradeBuy -> Hold$256.80 -> $160.07LowView Rating Details
10/19/2017MizuhoDowngradeBuy -> Neutral$193.00 -> $193.00N/AView Rating Details
10/18/2017Edward JonesReiterated RatingBuy -> HoldN/AView Rating Details
10/18/2017Sanford C. BernsteinSet Price TargetBuy$296.00 -> $252.00N/AView Rating Details
10/13/2017Piper JaffraySet Price TargetHold$227.00N/AView Rating Details
5/10/2017Goldman SachsDowngradeBuy -> Neutral$262.00HighView Rating Details
11/21/2016William BlairReiterated RatingMarket PerformN/AView Rating Details
(Data available from 4/26/2016 forward)

Earnings

Allergan (NYSE:AGN) Earnings History and Estimates Chart

Earnings by Quarter for Allergan (NYSE:AGN)

Allergan (NYSE:AGN) Earnings Estimates

2018 EPS Consensus Estimate: $15.48
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20183$3.37$3.39$3.38
Q2 20183$3.17$3.92$3.67
Q3 20183$3.85$3.89$3.87
Q4 20183$4.39$4.81$4.56

Allergan (NYSE AGN) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
4/30/2018$3.39N/AView Earnings Details
2/6/2018Q4 2017$4.74$4.86$4.2813 billion$4.3261 billionViewListenView Earnings Details
11/1/2017Q3 2017$4.06$4.15$4.0377 billion$4.0340 billionViewN/AView Earnings Details
8/3/2017Q2 2017$3.95$4.02$3.9461 billion$4.0074 billionViewListenView Earnings Details
5/9/2017Q1 2017$3.32$3.35$3.5325 billion$3.5730 billionViewListenView Earnings Details
2/8/2017Q416$3.76$3.90$3.77 billion$3.86 billionViewListenView Earnings Details
11/2/2016Q316$3.57$3.32$3.73 billion$3.62 billionViewListenView Earnings Details
8/8/2016Q216$3.34$3.35$4.10 billion$3.68 billionViewListenView Earnings Details
5/10/2016Q116$3.03$3.04$3.97 billion$3.80 billionViewListenView Earnings Details
2/22/2016Q415$3.36$3.41$4.20 billion$4.20 billionViewListenView Earnings Details
11/4/2015Q315$3.20$3.48$5.71 billion$4.10 billionViewN/AView Earnings Details
8/6/2015Q215$4.41$4.41$5.71 billion$5.76 billionViewN/AView Earnings Details
5/11/2015Q115$3.84$4.30$4.04 billion$4.23 billionViewListenView Earnings Details
2/18/2015Q414$3.67$3.91$3.84 billion$4.01 billionViewN/AView Earnings Details
11/5/2014Q414$1.83$2.17$1.9018 billion$1.9105 billionViewN/AView Earnings Details
11/5/2014Q314$3.10$3.19$3.63 billion$3.68 billionViewN/AView Earnings Details
8/5/2014Q314$1.76$1.78$1.78 billion$1.79 billionViewListenView Earnings Details
8/5/2014Q214$3.36$3.42$2.55 billion$2.67 billionViewN/AView Earnings Details
7/21/2014Q214$1.44$1.51$1.77 billion$1.83 billionViewN/AView Earnings Details
4/30/2014Q114$1.13$1.18$1.60 billion$1.6460 billionViewN/AView Earnings Details
4/30/2014Q114$3.23$3.49$2.59 billion$2.66 billionViewListenView Earnings Details
2/20/2014Q413$3.05$3.17$2.68 billion$2.78 billionViewListenView Earnings Details
2/4/2014Q413$1.34$1.12$1.65 million$1.66 millionViewN/AView Earnings Details
10/29/2013Q313$1.20$1.23$1.53 billion$1.23 billionViewListenView Earnings Details
10/29/2013Q313$2.09$2.09$2.04 billion$2.01 billionViewListenView Earnings Details
7/31/2013Q2 2013$1.20$1.22$1.56 billion$1.5977 billionViewN/AView Earnings Details
7/25/2013Q2 2013$2.00$2.01$1.9857 billion$1.9898 billionViewListenView Earnings Details
5/2/2013Q1 2013$1.86$1.99$1.97 billion$1.90 billionViewListenView Earnings Details
5/1/2013Q1 2013$0.96$0.98$1.44 billion$1.46 billionViewN/AView Earnings Details
2/19/2013Q4 2012$1.53$1.59$1.74 million$1.75 billionViewListenView Earnings Details
2/5/2013Q4 2012$1.20$1.15$1.51 million$1.48 millionViewN/AView Earnings Details
10/30/2012Q312$1.04$1.06$1.43 billion$1.39 billionViewN/AView Earnings Details
8/1/2012$1.06$1.07ViewN/AView Earnings Details
5/2/2012$0.87$0.86ViewN/AView Earnings Details
2/14/2012Q4 2011$1.75$1.77ViewN/AView Earnings Details
2/2/2012$1.00$1.00ViewN/AView Earnings Details
10/26/2011$0.90$0.92ViewN/AView Earnings Details
8/3/2011$0.95$0.96ViewN/AView Earnings Details
7/26/2011Q2 2011$1.00$1.01ViewN/AView Earnings Details
5/4/2011$0.74$0.77ViewN/AView Earnings Details
2/15/2011Q4 2010$0.93$0.93ViewN/AView Earnings Details
2/2/2011$0.89$0.88ViewN/AView Earnings Details
11/4/2010Q3 2010$0.84$0.85ViewN/AView Earnings Details
8/5/2010Q2 2010$0.81$0.83ViewN/AView Earnings Details
5/10/2010Q1 2010$0.74$0.63ViewN/AView Earnings Details
2/23/2010Q4 2009$0.72$0.85ViewN/AView Earnings Details
11/4/2009Q3 2009$0.65$0.66ViewN/AView Earnings Details
7/29/2009Q2 2009$0.57$0.61ViewN/AView Earnings Details
4/30/2009Q1 2009$0.49$0.58ViewN/AView Earnings Details
2/19/2009Q4 2008$0.50$0.53ViewN/AView Earnings Details
10/29/2008Q3 2008$0.46$0.48ViewN/AView Earnings Details
8/6/2008Q2 2008$0.48$0.48ViewN/AView Earnings Details
5/1/2008Q1 2008$0.51$0.55ViewN/AView Earnings Details
2/20/2008Q4 2007$0.31$0.35ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Allergan (NYSE:AGN) Dividend Information

Allergan pays an annual dividend of $2.88 per share, with a dividend yield of 1.83%. AGN's most recent quarterly dividend payment was Wednesday, March 28. Allergan pays out 17.61% of its earnings out as a dividend.
Most Recent Dividend:3/28/2018
Annual Dividend:$2.88
Dividend Yield:1.83%
Dividend Growth:141.00% (3 Year Average)
Payout Ratio:17.61% (Trailing 12 Months of Earnings)
18.47% (Based on This Year's Estimates)
17.43% (Based on Next Year's Estimates)
Frequency:Quarterly Dividend
Dividend Payments by Quarter for Allergan (NYSE:AGN)

Allergan (NYSE:AGN) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
2/9/2018quarterly$0.721.71%2/27/20182/28/20183/28/2018
10/27/2017quarterly$0.701.58%11/16/201711/17/201712/15/2017
8/2/2017Quarterly$0.701.12%8/16/20178/18/20179/15/2017
5/5/2017quarterly$0.700.01%5/16/20175/18/20176/15/2017
11/2/2016quarterly$0.702/24/20172/28/20173/28/2017
2/4/2015quarterly$0.050.09%2/5/20152/9/20153/20/2015
10/27/2014quarterly$0.0511/20/201412/11/2014
7/28/2014quarterly$0.050.12%8/13/20148/15/20149/5/2014
5/7/2014quarterly$0.050.12%5/21/20145/23/20146/13/2014
2/5/2014quarterly$0.050.17%2/26/20142/28/20143/21/2014
10/30/2013quarterly$0.050.22%11/18/201311/20/201312/11/2013
7/31/2013quarterly$0.050.22%8/20/20138/22/20139/12/2013
5/2/2013quarterly$0.050.2%5/21/20135/23/20136/13/2013
2/6/2013quarterly$0.050.18%2/26/20132/28/20133/21/2013
(Data available from 1/1/2013 forward)

Insider Trades

Allergan (NYSE AGN) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 0.37%
Institutional Ownership Percentage: 78.35%
Insider Trading History for Allergan (NYSE:AGN)
Institutional Ownership by Quarter for Allergan (NYSE:AGN)

Allergan (NYSE AGN) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/15/2018Maria Teresa HiladoInsiderBuy895$167.39$149,814.05View SEC Filing  
3/8/2018Brent L. SaundersCEOBuy3,300$152.53$503,349.00View SEC Filing  
3/8/2018Matthew M. WalshCFOBuy1,000$153.96$153,960.00View SEC Filing  
3/5/2018Joseph H. BoccuziDirectorBuy900$143.42$129,078.00View SEC Filing  
2/21/2018Matthew M WalshCFOBuy2,000$160.94$321,880.00View SEC Filing  
2/14/2018William MeuryInsiderSell58,879$160.62$9,457,144.98View SEC Filing  
12/7/2017Chris W. BodineDirectorBuy3,030$164.77$499,253.10View SEC Filing  
12/6/2017Brent L. SaundersChairmanBuy4,600$164.74$757,804.00View SEC Filing  
12/5/2017Christopher J. CoughlinDirectorBuy10,000$163.30$1,633,000.00View SEC Filing  
12/1/2017William MeuryInsiderSell11,807$173.89$2,053,119.23View SEC Filing  
5/18/2017Nesli BasgozDirectorSell1,889$220.45$416,430.05View SEC Filing  
3/2/2017Paul BisaroDirectorSell70,000$246.68$17,267,600.00274,226View SEC Filing  
12/8/2016Nesli BasgozDirectorSell500$188.72$94,360.00View SEC Filing  
11/21/2016Brent L. SaundersCEOBuy5,250$189.13$992,932.50View SEC Filing  
11/11/2016Maria Teresa HiladoCFOBuy1,422$210.64$299,530.0812,659View SEC Filing  
6/2/2016Maria Teresa HiladoCFOBuy661$241.57$159,677.7711,957View SEC Filing  
5/11/2016Nesli BasgozDirectorSell459$225.10$103,320.905,242View SEC Filing  
12/7/2015Nesli BasgozDirectorSell2,300$312.96$719,808.004,062View SEC Filing  
8/24/2015Paul BisaroChairmanBuy1,000$297.42$297,420.00421,755View SEC Filing  
8/21/2015Brent L SaundersCEOBuy1,000$301.94$301,940.00132,862View SEC Filing  
6/9/2015Nesli BasgozDirectorSell2,200$297.89$655,358.00View SEC Filing  
11/26/2014William MeuryInsiderSell4,550$269.14$1,224,587.00View SEC Filing  
9/8/2014Albert Paonessa IIIInsiderSell6,642$230.49$1,530,914.58View SEC Filing  
4/22/2014Scott ShermanEVPSell14,500$155.82$2,259,390.008,223View SEC Filing  
2/21/2014Louis Lavigne, Jr.DirectorSell5,400$125.79$679,266.0012,723View SEC Filing  
2/19/2014Dawn HudsonDirectorSell4,200$126.35$530,670.0011,600View SEC Filing  
2/19/2014Jeffrey EdwardsCFOSell38,900$126.39$4,916,571.0016,591View SEC Filing  
2/19/2014Raymond DiradoorianEVPSell23,000$126.66$2,913,180.006,401View SEC Filing  
2/18/2014Scott ShermanEVPSell5,001$125.74$628,825.748,220View SEC Filing  
1/14/2014Scott WhitcupVPSell42,000$117.80$4,947,600.0017,327View SEC Filing  
12/27/2013Julian GangolliVPSell52,500$110.05$5,777,625.00View SEC Filing  
12/20/2013Scott WhitcupVPSell33,000$108.80$3,590,400.0017,327View SEC Filing  
10/15/2013Trevor JonesDirectorSell2,000$90.14$180,280.007,142View SEC Filing  
9/16/2013Albert HummelDirectorSell6,200$137.81$854,422.0082,776View SEC Filing  
9/16/2013Trevor JonesDirectorSell2,000$89.78$179,560.008,142View SEC Filing  
9/4/2013George Fred WilkinsonInsiderSell16,749$138.00$2,311,362.00View SEC Filing  
9/4/2013Jack MichelsonDirectorSell6,064$139.54$846,170.56View SEC Filing  
8/29/2013David BuchenInsiderSell10,000$135.56$1,355,600.0097,373View SEC Filing  
8/26/2013Albert HummelDirectorSell40,000$134.44$5,377,600.0092,776View SEC Filing  
8/20/2013Paul BisaroCEOSell50,000$135.30$6,765,000.00469,232View SEC Filing  
8/15/2013Albert Paonessa IIIInsiderSell5,476$135.89$744,133.6433,812View SEC Filing  
8/15/2013Trevor JonesDirectorSell2,000$89.89$179,780.009,142View SEC Filing  
8/14/2013R Todd JoyceCFOSell15,000$137.98$2,069,700.0080,470View SEC Filing  
8/13/2013Albert HummelDirectorSell10,000$133.85$1,338,500.00132,776View SEC Filing  
8/12/2013Cathy KlemaDirectorSell1,667$133.03$221,761.0119,608View SEC Filing  
8/12/2013David BuchenInsiderSell17,000$133.03$2,261,510.0097,373View SEC Filing  
8/9/2013Ronald TaylorDirectorSell5,000$135.14$675,700.0027,942View SEC Filing  
8/6/2013Jeffrey EdwardsCFOSell69,200$91.17$6,308,964.0016,871View SEC Filing  
8/5/2013Charles EbertVPSell8,244$136.25$1,123,245.0019,970View SEC Filing  
8/5/2013Michel FeldmanDirectorSell10,000$136.94$1,369,400.0012,941View SEC Filing  
8/2/2013Robert StewartInsiderSell14,564$136.02$1,980,995.2873,891View SEC Filing  
7/15/2013Trevor M JonesDirectorSell2,000$91.15$182,300.00View SEC Filing  
6/17/2013Trevor M JonesDirectorSell2,000$101.25$202,500.00View SEC Filing  
5/15/2013Trevor M JonesDirectorSell2,000$103.40$206,800.00View SEC Filing  
5/9/2013Jeffrey L EdwardsCFOSell84,000$103.49$8,693,160.00View SEC Filing  
3/14/2013Charles M MayrInsiderSell1,000$91.77$91,770.00View SEC Filing  
3/12/2013Michael J FedidaDirectorSell8,000$89.00$712,000.00View SEC Filing  
11/26/2012Trevor M JonesDirectorSell2,500$91.30$228,250.00View SEC Filing  
10/5/2012David E I PyottCEOSell616,300$93.73$57,765,799.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Allergan (NYSE AGN) News Headlines

Source:
DateHeadline
Allergan (AGN) Expected to Announce Earnings of $3.36 Per ShareAllergan (AGN) Expected to Announce Earnings of $3.36 Per Share
www.americanbankingnews.com - April 25 at 3:20 PM
Notes From Allergan (AGN) Phase III ubrogepant Data - Piper JaffrayNotes From Allergan (AGN) Phase III ubrogepant Data - Piper Jaffray
www.streetinsider.com - April 25 at 11:00 AM
Meet the bankers involved in what could be a $64 billion takeover of the maker of AdderallMeet the bankers involved in what could be a $64 billion takeover of the maker of Adderall
www.businessinsider.com - April 25 at 11:00 AM
Allergan plc Stock Looks Cheap for Good ReasonsAllergan plc Stock Looks Cheap for Good Reasons
investorplace.com - April 25 at 10:25 AM
Can Allergan (AGN) Keep the Earnings Streak Alive in Q1?Can Allergan (AGN) Keep the Earnings Streak Alive in Q1?
www.zacks.com - April 24 at 10:29 AM
Urovant Sciences Strengthens Executive Management Team with Senior Hires and Establishes US Headquarters in ...Urovant Sciences Strengthens Executive Management Team with Senior Hires and Establishes US Headquarters in ...
www.prnewswire.com - April 24 at 10:29 AM
Allergans (AGN) Buy Rating Reaffirmed at CitigroupAllergan's (AGN) Buy Rating Reaffirmed at Citigroup
www.americanbankingnews.com - April 24 at 9:12 AM
Rival Botox Maker Says Patients Cant Wait for It to HitRival Botox Maker Says Patients Can't Wait for It to Hit
finance.yahoo.com - April 23 at 3:33 PM
Allergan (AGN) Earns Outperform Rating from Analysts at Evercore ISIAllergan (AGN) Earns Outperform Rating from Analysts at Evercore ISI
www.americanbankingnews.com - April 23 at 10:24 AM
Allergan (AGN) Given a $215.00 Price Target by Credit Suisse Group AnalystsAllergan (AGN) Given a $215.00 Price Target by Credit Suisse Group Analysts
www.americanbankingnews.com - April 23 at 9:18 AM
Allergan (AGN) to Release Quarterly Earnings on MondayAllergan (AGN) to Release Quarterly Earnings on Monday
www.americanbankingnews.com - April 23 at 4:28 AM
Vetr Downgrades Allergan (AGN) to HoldVetr Downgrades Allergan (AGN) to Hold
www.americanbankingnews.com - April 20 at 9:12 PM
Allergan (AGN) Upgraded at VetrAllergan (AGN) Upgraded at Vetr
www.americanbankingnews.com - April 20 at 5:52 PM
Allergan: The Shire Deal Is DOA And So Is The StockAllergan: The Shire Deal Is DOA And So Is The Stock
seekingalpha.com - April 20 at 3:36 PM
Allergan Declines to Bid on ShireAllergan Declines to Bid on Shire
finance.yahoo.com - April 20 at 3:36 PM
Allergan Will Not Make Offer for ShireAllergan Will Not Make Offer for Shire
www.bloomberg.com - April 20 at 10:56 AM
Allergan: Whats Going On?Allergan: What's Going On?
seekingalpha.com - April 20 at 10:56 AM
[$$] Takeda Sweetens Takeover Bid for Shire[$$] Takeda Sweetens Takeover Bid for Shire
finance.yahoo.com - April 20 at 10:56 AM
Allergan Showcases Leadership in Neurosciences with 25 Presentations at the American Academy of Neurology Annual Meeting in Los AngelesAllergan Showcases Leadership in Neurosciences with 25 Presentations at the American Academy of Neurology Annual Meeting in Los Angeles
www.prnewswire.com - April 20 at 8:10 AM
Shire retraces on Allergan passShire retraces on Allergan pass
seekingalpha.com - April 19 at 3:37 PM
CEO of Botox competitor: With scale, we think well have the same margins as the market leaderCEO of Botox competitor: 'With scale,' we think we'll have the same margins as the market leader
www.cnbc.com - April 19 at 3:37 PM
Allergan Issues Statement Regarding Press Speculation on its Strategic ReviewAllergan Issues Statement Regarding Press Speculation on its Strategic Review
www.prnewswire.com - April 19 at 3:37 PM
CEO of Botox competitor: 'With scale,' we think we'll hav...CEO of Botox competitor: 'With scale,' we think we'll hav...
finance.yahoo.com - April 19 at 3:37 PM
Allergan will not bid for Shire, sources tell CNBCAllergan will not bid for Shire, sources tell CNBC
finance.yahoo.com - April 19 at 3:37 PM
Allergan Reportedly Enters Fray To Buy Shire, Rivaling TakedaAllergan Reportedly Enters Fray To Buy Shire, Rivaling Takeda
finance.yahoo.com - April 19 at 3:37 PM
Allergan Weighing Shire Bid Has Investors Worried About Deja VuAllergan Weighing Shire Bid Has Investors Worried About Deja Vu
finance.yahoo.com - April 19 at 3:37 PM
Shire rejects $63 billion Takeda bid as Allergan drops pursuitShire rejects $63 billion Takeda bid as Allergan drops pursuit
finance.yahoo.com - April 19 at 3:37 PM
Blink and you missed it: Allergan doesnt plan to make a Shire bidBlink and you missed it: Allergan doesn't plan to make a Shire bid
finance.yahoo.com - April 19 at 3:37 PM
Allergan Does Not Intend to Make an Offer for Shire plc; Strategic Review ContinuesAllergan Does Not Intend to Make an Offer for Shire plc; Strategic Review Continues
finance.yahoo.com - April 19 at 3:37 PM
Allergan Does Not Intend to Make Offer for ShireAllergan Does Not Intend to Make Offer for Shire
finance.yahoo.com - April 19 at 3:37 PM
Allergan (AGN) Confirms Early Stages of Considering Shire (SHPG) Offer, No Offer Has Been MadeAllergan (AGN) Confirms Early Stages of Considering Shire (SHPG) Offer, No Offer Has Been Made
www.streetinsider.com - April 19 at 10:43 AM
BRIEF-Allergan Confirms It Is In Early Stages Of Considering Possible Offer For ShireBRIEF-Allergan Confirms It Is In Early Stages Of Considering Possible Offer For Shire
www.reuters.com - April 19 at 10:43 AM
Allergan in talks to acquire Shire, competing against Takeda PharmaceuticalAllergan in talks to acquire Shire, competing against Takeda Pharmaceutical
www.cnbc.com - April 19 at 10:43 AM
Allergan shares plummet 6% on Shire bid interest, while Shire surges 8%Allergan shares plummet 6% on Shire bid interest, while Shire surges 8%
finance.yahoo.com - April 19 at 10:43 AM
Allergan (AGN) Given Average Rating of "Hold" by BrokeragesAllergan (AGN) Given Average Rating of "Hold" by Brokerages
www.americanbankingnews.com - April 19 at 3:40 AM
Allergan to Post Q1 2018 Earnings of $3.39 Per Share, SunTrust Banks Forecasts (AGN)Allergan to Post Q1 2018 Earnings of $3.39 Per Share, SunTrust Banks Forecasts (AGN)
www.americanbankingnews.com - April 18 at 7:58 AM
Stifel Says Allergan Could Use A Face-Lift, Initiates Coverage With HoldStifel Says Allergan Could Use A Face-Lift, Initiates Coverage With Hold
finance.yahoo.com - April 17 at 3:43 PM
New Research Coverage Highlights Exelixis, Verizon Communications, AT&T, Snap, Allergan plc, and QUALCOMM ...New Research Coverage Highlights Exelixis, Verizon Communications, AT&T, Snap, Allergan plc, and QUALCOMM ...
globenewswire.com - April 17 at 10:45 AM
Allergan to pay $3.5 mln over US claims of defective Lap-BandsAllergan to pay $3.5 mln over US claims of defective Lap-Bands
www.reuters.com - April 17 at 10:45 AM
Allergan (AGN) Downgraded by VetrAllergan (AGN) Downgraded by Vetr
www.americanbankingnews.com - April 17 at 9:25 AM
Stifel Nicolaus Initiates Coverage on Allergan (AGN)Stifel Nicolaus Initiates Coverage on Allergan (AGN)
www.americanbankingnews.com - April 17 at 7:39 AM
Allergan (AGN) Given a $255.00 Price Target at CowenAllergan (AGN) Given a $255.00 Price Target at Cowen
www.americanbankingnews.com - April 16 at 12:05 PM
Form DEFA14A Allergan plcForm DEFA14A Allergan plc
www.streetinsider.com - April 16 at 10:27 AM
Allergan (AGN) Price Target Raised to $278.00 at Wells FargoAllergan (AGN) Price Target Raised to $278.00 at Wells Fargo
www.americanbankingnews.com - April 13 at 6:01 PM
What does Allergan plc’s (NYSE:AGN) Balance Sheet Tell Us About Its Future?What does Allergan plc’s (NYSE:AGN) Balance Sheet Tell Us About Its Future?
finance.yahoo.com - April 13 at 3:39 PM
Allergan Announces Launch of the TrueTear® Intranasal Neurostimulation Device During 2018 ASCRS-ASOA Annual ...Allergan Announces Launch of the TrueTear® Intranasal Neurostimulation Device During 2018 ASCRS-ASOA Annual ...
www.prnewswire.com - April 13 at 11:00 AM
Pfizer, Allergan Win Out With Tax BenefitsPfizer, Allergan Win Out With Tax Benefits
www.bloomberg.com - April 12 at 3:40 PM
Allergan (AGN) Given a $191.00 Price Target at Cantor FitzgeraldAllergan (AGN) Given a $191.00 Price Target at Cantor Fitzgerald
www.americanbankingnews.com - April 12 at 3:26 PM
Allergan (AGN) Earns Outperform Rating from Wells FargoAllergan (AGN) Earns Outperform Rating from Wells Fargo
www.americanbankingnews.com - April 12 at 2:19 PM
Deutsche Bank Reiterates Buy Rating for Allergan (AGN)Deutsche Bank Reiterates Buy Rating for Allergan (AGN)
www.americanbankingnews.com - April 12 at 11:07 AM

SEC Filings

Allergan (NYSE:AGN) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Allergan (NYSE:AGN) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Allergan (NYSE AGN) Stock Chart for Thursday, April, 26, 2018

Loading chart…

This page was last updated on 4/26/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.